

**Medical Policy**



**Title: Scanning Computerized Ophthalmic Diagnostic Imaging Devices**

Related Policy:	▪ <i>Optical Coherence Tomography of the Anterior Eye Segment</i>
-----------------	---

<b>Professional</b>	<b>Institutional</b>
Original Effective Date: January 1, 2001	Original Effective Date: May 31, 2010
Revision Date(s): April 18, 2001; April 24, 2001; September 18, 2002; May 10, 2005; May 19, 2005; February 1, 2007; March 1, 2007; April 19, 2007, May 9, 2007; November 1, 2007; April 30, 2010; October 26, 2010; February 16, 2011; January 1, 2012; January 15, 2013; January 22, 2013; July 30, 2013; April 28, 2015; August 19, 2015; October 1, 2015; October 1, 2016; October 12, 2016; May 12, 2017; October 1, 2017; April 11, 2018; August 1, 2018; April 15, 2019; September 27, 2019; May 5, 2021; July 12, 2022	Revision Date(s): October 26, 2010; February 16, 2011; January 1, 2012; January 15, 2013; January 22, 2013; July 30, 2013; April 28, 2015; August 19, 2015; October 1, 2015; October 1, 2016; October 12, 2016; May 12, 2017; October 1, 2017; April 11, 2018; August 1, 2018; April 15, 2019; September 27, 2019; May 5, 2021; July 12, 2022
Current Effective Date: September 27, 2019	Current Effective Date: September 27, 2019

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

Populations	Interventions	Comparators	Outcomes
Individuals: • With glaucoma or suspected glaucoma	Interventions of interest are: • Imaging of the optic nerve and retinal nerve fiber layer	Comparators of interest are: • Clinical assessment alone	Relevant outcomes include: • Test accuracy • Symptoms • Morbid events • Functional outcomes • Medication use
Individuals: • With glaucoma or suspected glaucoma	Interventions of interest are: • Evaluation of ocular blood flow	Comparators of interest are: • Clinical assessment alone	Relevant outcomes include: • Test accuracy • Symptoms • Morbid events • Functional outcomes • Medication use

## DESCRIPTION

Several techniques have been developed to measure the thickness of the optic nerve and retinal nerve fiber layer as a method to diagnose glaucoma. Measurement of ocular blood flow is also being evaluated as a diagnostic tool for glaucoma.

## OBJECTIVE

The objective of this evidence review is to assess whether methods that evaluate the optic nerve and retinal nerve fiber layer or that evaluate ocular blood flow improve the net health outcome in individuals with glaucoma or who are suspected to have glaucoma.

## BACKGROUND

### Diagnosis and Management

A comprehensive ophthalmologic exam is required for the diagnosis of glaucoma, but no single test is adequate to establish diagnosis. A comprehensive ophthalmologic examination includes assessment of the optic nerve, evaluation of visual fields, and measurement of ocular pressure. The presence of characteristic changes in the optic nerve or abnormalities in visual field, together with increased intraocular pressure (IOP), is sufficient for a definitive diagnosis. However, some patients will show ophthalmologic evidence of glaucoma with normal IOPs. These cases of normal-tension glaucoma are considered to be a type of primary open-angle glaucoma. Angle-closure glaucoma is another type of glaucoma associated with an increase in IOP. The increased IOP in angle-closure glaucoma arises from a reduction in aqueous outflow from the eye due to a closed angle in the anterior chamber.

Conventional management of patients with glaucoma principally involves drug therapy to control elevated IOPs, and serial evaluation of the optic nerve, to follow disease progression. Standard methods of evaluation include careful direct examination of the optic nerve using ophthalmoscopy or stereo photography or evaluation of visual fields. There is interest in developing more objective, reproducible techniques both to document optic nerve damage and to detect early changes in the optic nerve and retinal nerve fiber layer before the development of permanent visual field deficits. Specifically, evaluating changes in retinal nerve fiber layer thickness has been investigated as a technique to diagnose and monitor glaucoma. However,

IOP reduction is not effective in decreasing disease progression in a significant number of patients, and in patients with normal-tension glaucoma, there is never an increase in IOP. It has been proposed that vascular dysregulation is a significant cause of damage to the retinal nerve fiber layer, and there is interest in measuring ocular blood flow as both a diagnostic and a management tool for glaucoma. Changes in blood flow to the retina and choroid may be particularly relevant for diagnosis and treatment of normal-tension glaucoma. A variety of techniques have been developed, as described below. (Note: This evidence review only addresses techniques related to the evaluation of the optic nerve, retinal nerve fiber layer, or blood flow to the retina and choroid in patients with glaucoma.)

## **TECHNIQUES TO EVALUATE THE OPTIC NERVE AND RETINAL NERVE FIBER LAYER**

### **Confocal Scanning Laser Ophthalmoscopy**

Confocal scanning laser ophthalmoscopy is an image acquisition technique intended to improve the quality of the eye examination compared with standard ophthalmologic examination. A laser is scanned across the retina along with a detector system. Only a single spot on the retina is illuminated at any time, resulting in a high-contrast image of great reproducibility that can be used to estimate retinal nerve fiber layer thickness. In addition, this technique does not require maximal mydriasis, which may be problematic in patients with glaucoma. The Heidelberg Retinal Tomograph is a commonly used technology.

### **Scanning Laser Polarimetry**

The retinal nerve fiber layer is birefringent (i.e., birefractive), meaning that it causes a change in the state of polarization of a laser beam as it passes. A 780-nm diode laser is used to illuminate the optic nerve. The polarization state of the light emerging from the eye is then evaluated and correlated with retinal nerve fiber layer thickness. Unlike confocal scanning laser ophthalmoscopy, scanning laser polarimetry can directly measure the thickness of the retinal nerve fiber layer. GDx is a common scanning laser polarimetry device. GDx contains a normative database and statistical software package that compares scan results with age-matched normal subjects of the same ethnic origin. The advantages of this system are that images can be obtained without pupil dilation and evaluation can be completed in 10 minutes. Current instruments have added enhanced and variable corneal compensation technology to account for corneal polarization.

### **Optical Coherence Tomography**

Optical coherence tomography uses near-infrared light to provide direct cross-sectional measurement of the retinal nerve fiber layer. The principles employed are similar to those used in B-mode ultrasound except light, not sound, is used to produce the 2-dimensional images. The light source can be directed into the eye through a conventional slit-lamp biomicroscope and focused onto the retina through a typical 78-diopter lens. This system requires dilation of the patient's pupil. Optical coherence tomography analysis software is being developed to include optic nerve head parameters with spectral domain optical coherence tomography, analysis of macular parameters, and hemodynamic parameters with Doppler optical coherence tomography and optical coherence tomography angiography.

### **Pulsatile Ocular Blood Flow**

The pulsatile variation in ocular pressure results from the flow of blood into the eye during cardiac systole. Pulsatile ocular blood flow can thus be detected by the continuous monitoring

of IOP. The detected pressure pulse can then be converted into a volume measurement using the known relation between ocular pressure and ocular volume. Pulsatile blood flow is primarily determined by the choroidal vessels, particularly relevant to patients with glaucoma because the optic nerve is supplied in large part by choroidal circulation.

### **Techniques to Measure Ocular Blood Flow**

A number of techniques have been developed to assess ocular blood flow. They include laser speckle flowgraphy, color Doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imaging.<sup>1</sup>

#### **Laser Speckle Flowgraphy**

Laser speckle is detected when a coherent light source such as laser light is dispersed from a diffusing surface such as retinal and choroidal vessels and the circulation of the optic nerve head. The varying patterns of light can be used to determine red blood cell velocity and retinal blood flow. However, due to differences in the tissue structure in different eyes, flux values cannot be used for comparisons between eyes. This limitation may be overcome by subtracting background choroidal blood flow results from the overall blood flow results in the region of interest.

#### **Color Doppler Imaging**

Color Doppler imaging has also been investigated as a technique to measure the blood flow velocity in the retinal and choroidal arteries. This technique delivers ultrasound in pulsed Doppler mode with a transducer set on closed eyelids. The examination takes 30 to 40 minutes and is most effective for the mean velocity of large ophthalmic vessels such as the ophthalmic artery, the central retinal artery, and the short posterior ciliary arteries. However, total blood flow cannot be determined with this technique, and imaging is highly dependent on probe placement.

#### **Doppler Fourier Domain Optical Coherence Tomography**

Doppler Fourier domain optical coherence tomography is a noncontact imaging technique that detects the intensity of the light scattered back from erythrocytes as they move in the vessels of the ocular tissue. This induces a frequency shift that represents the velocity of the blood in the ocular tissue.

#### **Laser Doppler Velocimetry**

Laser Doppler velocimetry compares the frequency of reflected laser light from a moving particle with stationary tissue.

#### **Confocal Scanning Laser Doppler Flowmetry**

Confocal scanning laser Doppler flowmetry combines laser Doppler flowmetry with confocal scanning laser tomography. Infrared laser light is used to scan the retina, and the frequency and amplitude of Doppler shifts are determined from the reflected light. Determinations of blood velocity and blood volume are used to compute the total blood flow and create a physical map of retinal flow values.

## REGULATORY STATUS

A number of confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography devices have been cleared by the U.S. Food and Drug Administration (FDA) through the 510(k) process for imaging the posterior eye segment. For example, the RTVue XR optical coherence tomography Avanti™ (Optovue) is an optical coherence tomography system indicated for the in vivo imaging and measurement of the retina, retinal nerve fiber layer, and optic disc as a tool and aid in the clinical diagnosis and management of retinal diseases. The RTVue XR optical coherence tomography Avanti™ with Normative Database is a quantitative tool for comparing retina, retinal nerve fiber layer, and optic disk measurements in the human eye with a database of known normal subjects. It is intended as a diagnostic device to aid in the detection and management of ocular diseases. In 2016, the RTVue XR optical coherence tomography and Avanti™ with AngioVue™ Software was cleared by the FDA through the 510(k) process (K153080) as an aid in the visualization of vascular structures of the retina and choroid.

FDA product code: HLI, OBO.

In 2012, the iExaminer™ (Welch Allyn) was cleared for marketing by the FDA through the 510(k) process. The iExaminer™ consists of a hardware adapter and associated software (iPhone® App) to capture, store, send, and retrieve images from the PanOptic™ Ophthalmoscope (Welch Allyn) using an iPhone.

FDA product code: HKI.

**Table 1. Selected Ocular Imaging Devices Cleared by the U.S. Food and Drug Administration**

Device	Manufacturer	Date Cleared	510.k No.	Indication
RESCAN 700 CALLISTO eye	Carl Zeiss Meditec AG	1/11/2019	K180229	Imaging of optic nerve and retinal nerve fiber layer
Retina Workplace	Carl Zeiss Meditec Inc	10/24/2018	K182318	Imaging of optic nerve and retinal nerve fiber layer
Spectralis HRA+OCT and variants with High Magnification Module	Heidelberg Engineering GmbH	10/18/2018	K182569	Imaging of optic nerve and retinal nerve fiber layer
Spectralis HRA+OCT and variants with OCT Angiography Module	Heidelberg Engineering GmbH	9/13/2018	K181594	Imaging of optic nerve and retinal

<b>Device</b>	<b>Manufacturer</b>	<b>Date Cleared</b>	<b>510.k No.</b>	<b>Indication</b>
				nerve fiber layer
Spectralis HRA + OCT and variants	Heidelberg Engineering GmbH	8/30/2018	K173648	Imaging of optic nerve and retinal nerve fiber layer
Image Filing Software NAVIS-EX	Nidek Co. Ltd	7/19/2018	K181345	Imaging of optic nerve and retinal nerve fiber layer
Avanti	Optovue Inc.	6/8/2018	K180660	Imaging of optic nerve and retinal nerve fiber layer
P200TE	Optos plc	2/28/2018	K173707	Imaging of optic nerve and retinal nerve fiber layer
DRI OCT Triton	Topcon Corporation	1/19/2018	K173119	Imaging of optic nerve and retinal nerve fiber layer
IMAGENet 6 Ophthalmic Data System	Topcon Corporation	11/1/2017	K171370	Imaging of optic nerve and retinal nerve fiber layer
Spectralis HRA + OCT and variants Spectralis FA+OCT Spectralis ICGA+OCT Spectralis OCT Blue Peak Spectralis OCT with Multicolor	Heidelberg Engineering GmbH	11/1/2017	K172649	Imaging of optic nerve and retinal nerve fiber layer
PRIMUS	Carl Zeiss Suzhou Co. Ltd.	6/21/2017	K163195	Imaging of optic nerve and retinal nerve fiber layer
Retina Workplace	Carl Zeiss Meditec AG	6/21/2017	K170638	Imaging of optic nerve and retinal

<b>Device</b>	<b>Manufacturer</b>	<b>Date Cleared</b>	<b>510.k No.</b>	<b>Indication</b>
				nerve fiber layer
iVue	Optovue Inc.	6/9/2017	K163475	Imaging of optic nerve and retinal nerve fiber layer
3D OCT-1 Maestro	Topcon Corporation	3/3/2017	K170164	Imaging of optic nerve and retinal nerve fiber layer
EnFocus 2300 EnFocus 4400	Bioptigen Inc.	12/9/2016	K162783	Imaging of optic nerve and retinal nerve fiber layer
PLEX Elite 9000 SS-OCT	CARL ZEISS MEDITEC INC.	10/26/2016	K161194	Imaging of optic nerve and retinal nerve fiber layer
3D OCT-1 Maestro	Topcon Corporation	7/28/2016	K161509	Imaging of optic nerve and retinal nerve fiber layer
LSFG-NAVI	Softcare Co. Ltd	5/12/2016	K153239	Imaging of optic nerve and retinal nerve fiber layer
Spectralis HRA + OCT and variants (e.g.s below) Spectralis FA+OCT Spectralis ICGA+OCT Spectralis OCT Blue Peak Spectralis OCT with Multicolor	Heidelberg Engineering GmbH	5/6/2016	K152205	Imaging of optic nerve and retinal nerve fiber layer
RTVue XR OCT Avanti with AngioVue Software	OPTOVUE INC.	2/11/2016	K153080	Imaging of optic nerve and retinal nerve fiber layer
EnFocus 2300 EnFocus 4400	BIOPTIGEN INC.	12/2/2015	K150722	Imaging of optic nerve and retinal

<b>Device</b>	<b>Manufacturer</b>	<b>Date Cleared</b>	<b>510.k No.</b>	<b>Indication</b>
				nerve fiber layer
Optical Coherence Tomography	CARL ZEISS MEDITEC INC	9/1/2015	K150977	Imaging of optic nerve and retinal nerve fiber layer
OCT-Camera	OptoMedical Technologies GmbH	3/4/2015	K142953	Imaging of optic nerve and retinal nerve fiber layer
RESCAN 700 CALLISTO EYE	CARL ZEISS MEDITEC AG	11/18/2014	K141844	Imaging of optic nerve and retinal nerve fiber layer
PROPPER INSIGHT BINOCULAR INDIRECT OPHTHALMOSCOPE	PROPPER MANUFACTURING CO.INC.	9/17/2014	K141638	Imaging of optic nerve and retinal nerve fiber layer
CENTERVUE MACULAR INTEGRITY ASSESSMENT	CENTERVUE SPA	4/23/2014	K133758	Imaging of optic nerve and retinal nerve fiber layer
AMICO DH-W35 OPHTHALMOSCOPE SERIES	AMICO DIAGNOSTIC INCORPORATED	3/26/2014	K131939	Imaging of optic nerve and retinal nerve fiber layer
IVUE 500	OPTOVUE INC.	3/19/2014	K133892	Imaging of optic nerve and retinal nerve fiber layer
RS-3000 ADVANCE	NIDEK CO. LTD.	2/19/2014	K132323	Imaging of optic nerve and retinal nerve fiber layer



**POLICY**

- A. Scanning Laser Ophthalmoscopy (SLO) test is allowable for the diagnosis and the monitoring of the optic nerve, retinal conditions and glaucoma. Testing may be allowed every year. If the testing is done more frequently than every year, consultant review will be required.
- B. Optical Coherence Tomography (OCT) test is allowed for the diagnoses, listed below, monitoring for retinal conditions, and ocular toxicity secondary to high-risk medications (i.e., chloroquine [Aralen], hydroxychloroquine [Plaquenil], Interferon alpha-2b, Amiodarone, tamoxifen citrate [Nolvadex], fingolimod [Gilenya], Seroquel).

## Repeat testing:

1. If Exudative Age-Related Macular Degeneration (AMD):  
Repeat OCT will significantly help guide the need for retreatment (with photodynamic therapy [PDT] or intravitreal injection treatments) in conjunction with intravenous fluorescein angiography (IVF) / indocyanine green (ICG). Maximum of 8 per year linked to intravitreal injections.
  2. If Macular Drusen:  
Repeat annually, only if subjective visual changes or suspicion of choroidal neovascularization: if more than 2 studies per year, then documentation is required
  3. If Diabetic Macular Edema (DME):  
Maximum of 8 per year linked to intravitreal injections or laser treatment.
  4. If Retinal Detachment (RD):  
Repeat pre-treatment and post-surgical at 2 months (maximum of 2).
  5. If Epiretinal Membrane (ERM):  
Repeat pre-treatment and post-surgical (maximum of 4 per year) if with macular edema.
  6. If Macular Hole:  
Repeat pre-treatment and post-treatment (maximum of 4 per year) in cases of partially closed hole.
  7. If Cystoid Macular Edema:  
Repeat every 2 months during acute treatment.
  8. If Branch Retinal Vein Occlusion (BRVO):  
Maximum of 8 per year linked to intravitreal injections.
  9. If Central Retinal Vein Occlusion (CRVO):  
Maximum of 8 per year linked to intravitreal injections.
  10. If Vitreomacular Traction / Adhesion:  
Maximum of 4 per year.
- C. OCT is also allowed for diagnosing and monitoring glaucoma, nerve fiber layer, and optic nerve conditions. Testing may be allowed every year. If the testing is done more frequently than every year, consultant review will be required.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## **RATIONALE**

This evidence review has been updated regularly with searches of the PubMed database. The most recent literature update was performed through January 26, 2022.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Glaucoma is characterized by degeneration of the optic nerve (optic disc). Elevated intraocular pressure (IOP) has long been thought to be the primary etiology, but the relation between IOP and optic nerve damage varies among patients, suggesting a multifactorial origin. For example, some patients with clearly elevated IOP will show no optic nerve damage, while others with marginal or no pressure elevation will show optic nerve damage. The association between glaucoma and other vascular disorders (e.g., diabetes, hypertension) suggests vascular factors may play a role in glaucoma. Specifically, it has been hypothesized that reductions in blood flow to the optic nerve may contribute to the visual field defects associated with glaucoma.

## **IMAGING OF THE OPTIC NERVE AND RETINAL NERVE FIBER LAYER**

### **Clinical Context and Test Purpose**

The purpose of optic nerve and retinal nerve fiber layer imaging in patients with or suspected to have glaucoma is to inform a decision about appropriate treatment.

The question addressed in this evidence review is: Do imaging techniques for the optic nerve and retinal nerve fiber layer improve the net health outcome in individuals with glaucoma or suspected glaucoma?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population is patients with glaucoma or who are suspected to have glaucoma and are being evaluated for diagnosis and monitoring of glaucoma progression.

### ***Interventions***

The tests being considered for assessment of the optic nerve and retinal nerve fiber layer include confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography. These tests are considered add-ons to the standard clinical evaluation.

### **Comparators**

There is no single criterion standard for the diagnosis of glaucoma. This diagnosis is made from a combination of visual field testing, IOP measurement, and optic nerve and retinal nerve fiber layer assessment by an ophthalmologist.

### **Outcomes**

Relevant outcomes include the clarity of the images and how reliable the test is at evaluating the optic nerve and nerve fiber layer changes. Demonstration that the information can be used to improve patient outcomes is essential for determining the utility of an imaging technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence needs to be constructed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP lowering medications used to treat glaucoma.

For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer-term follow-up would be needed to detect changes in visual field or retinal nerve fiber layer. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.

### **Study Selection Criteria**

For the evaluation of clinical validity of optic nerve and retinal nerve fiber layer imaging, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

## **REVIEW OF EVIDENCE**

### **Systematic Reviews**

In 2012, the Agency for Healthcare Research and Quality published a comparative effectiveness review of screening for glaucoma.<sup>2</sup> Included were randomized controlled trials (RCTs), quasi-RCTs, observational cohort and case-control studies, and case series with more than 100 participants. The interventions evaluated included ophthalmoscopy, fundus photography or computerized imaging (i.e., optical coherence tomography, retinal tomography, scanning laser polarimetry), pachymetry (i.e., corneal thickness measurement), perimetry, and tonometry. No evidence was identified that addressed whether an open-angle glaucoma screening program led

to a reduction in IOP, less visual impairment, reduction in visual field loss or optic nerve damage, or improvement in patient-reported outcomes. No evidence was identified on harms of a screening program. Over 100 studies were identified on the diagnostic accuracy of screening tests. However, due to the lack of a definitive diagnostic reference standard and heterogeneity in study designs, synthesis of results could not be completed.

A Cochrane review (2015) assessed the diagnostic accuracy of optic nerve head and retinal nerve fiber layer imaging for glaucoma.<sup>3</sup> Included were 103 case-control studies and 3 cohort studies (N=16,260 eyes) that evaluated the accuracy of recent commercial versions of optical coherence tomography (spectral domain), Heidelberg Retinal Tomograph III, or scanning laser polarimetry (with the variable corneal compensator or enhanced corneal compensation) for diagnosing glaucoma. The population was patients referred for suspected glaucoma, typically due to an elevated IOP, abnormal optic disc appearance, and/or an abnormal visual field identified in primary eye care. Population-based screening studies were excluded. Most comparisons examined different parameters within the 3 tests, and the parameters with the highest diagnostic odds ratio were compared. The 3 tests (optical coherence tomography, Heidelberg Retinal Tomograph III, scanning laser polarimetry) had similar diagnostic accuracy. Specificity was close to 95%, while sensitivity was 70%. Because a case-control design with healthy participants and glaucoma patients was used in nearly all studies, concerns were raised about the potential for bias, overestimation of accuracy, and applicability of the findings to clinical practice.

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

A technology assessment, conducted by Lin et al (2007) for the American Academy of Ophthalmology (AAO), reviewed 159 studies, published between 2003 and 2006, evaluating optic nerve head and retinal nerve fiber layer devices used to diagnose or detect glaucoma progression.<sup>4</sup> The assessment concluded: "The information obtained from imaging devices is useful in clinical practice when analyzed in conjunction with other relevant parameters that define glaucoma diagnosis and progression." Management changes for patients diagnosed with glaucoma may include the use of IOP lowering medications, monitoring for glaucoma progression, and potentially surgery to slow the progression of glaucoma.

### **Section Summary: Imaging of the Optic Nerve and Retinal Nerve Fiber Layer**

Numerous studies and systematic reviews have described findings from patients with glaucoma using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography. Although the specificity in these studies was high, it is likely that accuracy was overestimated due to the case-control designs used in the studies. The literature and specialty society guidelines have indicated that optic nerve analysis using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography are

established add-on tests that can be used with other established tests to improve the diagnosis and direct management of patients with glaucoma and those who are glaucoma suspects. Management changes for patients diagnosed with glaucoma may include the use of IOP lowering medications, monitoring for glaucoma progression, and potentially surgery.

## **EVALUATION OF OCULAR BLOOD FLOW**

### **Clinical Context and Test Purpose**

The diagnosis and monitoring of optic nerve damage are essential for evaluating the progression of glaucoma and determining appropriate treatment. Measurement of ocular blood flow has been studied as a technique to evaluate patients with glaucoma or suspected glaucoma. One potential application is the early detection of normal-tension glaucoma.<sup>5</sup>

The purpose of evaluating ocular blood flow in patients who have glaucoma or suspected glaucoma is to inform a decision about appropriate treatment.

The question addressed in this evidence review is: Does evaluation of ocular blood flow using various techniques (e.g., color Doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, retinal functional imager) in patients with glaucoma or suspected glaucoma improve diagnosis and monitoring of glaucoma?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population is patients with glaucoma or suspected glaucoma who are being evaluated for diagnosis and monitoring of glaucoma progression. These tests may have particular utility for normal tension glaucoma.

### ***Interventions***

The tests being considered for assessment of the ocular blood flow include color doppler imaging, Doppler Fourier domain optical coherence tomography, laser Doppler velocimetry, confocal scanning laser Doppler flowmetry, and retinal functional imager.

Many of these procedures are performed with specialized equipment. While reports of use are longstanding (e.g., Bafa et al [2001]<sup>6</sup>), investigators have commented on the complexity of these parameters<sup>7</sup> and have noted that many of these technologies are not commonly used in clinical settings.<sup>8</sup>

### ***Comparators***

There is no criterion standard for the diagnosis of glaucoma. The diagnosis of glaucoma is made using a combination of visual field testing, IOP measurements, and optic nerve and retinal nerve fiber layer assessment.

### ***Outcomes***

Relevant outcomes include the reliability of the test for evaluating ocular blood flow and the association between ocular blood flow parameters and glaucoma progression. Demonstration that the information can be used to improve patient outcomes is essential to determining the

utility of a diagnostic technology. Although direct evidence on the impact of the imaging technology from controlled trials would be preferred, in most cases, a chain of evidence is needed to determine whether there is a tight linkage between the technology and improved health outcomes. The outcomes relevant to this evidence review are IOP, loss of vision, and changes in IOP lowering medications used to treat glaucoma.

For patients with manifest glaucoma, the relevant period of follow-up is the immediate diagnosis of glaucoma. For patients with suspected glaucoma, longer-term follow-up would be needed to detect changes in IOP and loss of vision. Clinical utility might be demonstrated by a change in the management and reduction in glaucoma progression across follow-up.

### **Study Selection Criteria**

For the evaluation of clinical validity of optic nerve and retinal nerve fiber layer imaging, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

A technology assessment, conducted by WuDunn et al (2021) for the AAO, reviewed 75 articles published through June 2020, evaluating the utility of optical coherence tomography angiography of the peripapillary or macular regions to help detect glaucomatous damage associated with the diagnosis of primary open-angle glaucoma.<sup>9</sup> Per the AAO, the majority of data demonstrates that peripapillary microcirculation measured by vessel density on optical coherence tomography angiography is decreased in glaucomatous versus healthy eyes. Therefore, this technology can be helpful in detecting vessel density loss associated with glaucoma. Furthermore, peripapillary, macular, and choroidal vessel density parameters may complement visual field and structural optical coherence tomography measurements in the diagnosis of glaucoma.

### **Systematic Review**

Gu et al (2021) published a systematic review with meta-analysis evaluating the diagnostic value of laser speckle flowgraphy in glaucoma by investigating the mean blur rate in the optic nerve head.<sup>10</sup> A total of 15 studies, including 692 glaucomatous and 386 healthy eyes, were included; only 1 study was based in the US (Tables 2 and 3). Results are summarized in Table 4. Briefly, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the entire area, indicating that blood flow velocity in all areas of the optic nerve head was lower in glaucomatous eyes. Furthermore, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the tissue area, indicating that there is insufficient blood supply in the deep fundus tissues and optic nerve head ischemia in glaucomatous eyes. Lastly, the mean blur rate was significantly reduced in glaucomatous versus healthy eyes in the vascular area, indicating that patients with glaucoma have an insufficient retinal blood supply.

The authors concluded that while laser speckle flowgraphy is a feasible diagnostic tool for glaucoma, more prospective studies are needed to fully evaluate this technology.

**Table 2. Comparison of Trials/Studies Included in SR & M-A**

Study	Gu et al (2021) <sup>10</sup> ,
Aizawa (2011)	●
Gardiner (2019)	●
Iida (2017)	●
InoueYanagimachi (2018)	●
Kiyota (2017)	●
Kiyota (2017)	●
Kiyota (2018)	●
Kobayashi (2014)	●
Kohmoto (2019)	●
Kuroda (2020)	●
Mursch-Edlmayr (2018)	●
Mursch-Edlmayr (2019)	●
Mursch-Edlmayr (2020)	●
Shiga (2016)	●
Takeyama (2018)	●

M-A: meta-analysis; SR: systematic review.

**Table 3. SR & M-A Characteristics**

Study	Dates	Trials	Participants	N	Design	Duration
Gu et al (2021) <sup>10</sup> ,	Through Dec 2020	15	Patients with glaucomatous or healthy eyes undergoing laser speckle flowgraphy to examine the ocular blood flow. The majority of participants in the included studies were Japanese (N=11 studies).	692 glaucomatous eyes; 386 healthy eyes.	Observational studies or randomized controlled trials.	N/A.

M-A: meta-analysis; N/A: not applicable; SR: systematic review.

**Table 4. SR & M-A Results**

Study	MBR – entire area	MBR – tissue area	MBR – vascular area
Gu et al (2021) <sup>10</sup> ,			
Total N			
Glaucomatous eyes	541	660	573
Healthy eyes	254	372	268
MD (95% CI)	-5.59 (-6.19 to -4.99)	-2.2 (-2.49 to -1.91)	-5.92 (-7.77 to -4.07)
p-value	.1	.07	.0003

CI: confidence interval; M-A: meta-analysis; MBR: mean blur rate; MD: mean difference; SR: systematic review.

### Nonrandomized Studies

Abegao Pinto et al (2016) reported on the results from the prospective, cross-sectional, case-control, Leuven Eye Study, which included 614 individuals who had primary open-angle glaucoma (n=214), normal tension glaucoma (n=192), ocular hypertension (n=27), suspected glaucoma (n=41), or healthy controls (n=140).<sup>11</sup> The study objective was to identify the blood flow parameters most highly associated with glaucoma using technology commonly available in an ophthalmologist's office or hospital radiology department. Assessment of ocular blood flow included color doppler imaging, retinal oximetry, dynamic contour tonometry, and optical coherence tomography enhanced-depth imaging of the choroid. The glaucoma groups had higher perfusion pressure than controls (p<.001), with lower velocities in both central retinal vessels (p<.05), and choroidal thickness asymmetries. The normal tension glaucoma group, but not the primary open-angle glaucoma group, had higher retinal venous saturation than healthy controls (p=.005). There were no significant differences in macular scans. The diagnostic accuracy and clinical utility were not addressed.

Kuryshva et al (2017) compared ocular blood flow with choroidal thickness to determine which had a higher diagnostic value for detecting early glaucoma.<sup>12</sup> Thirty-two patients with pre-perimetric glaucoma were matched with 30 control patients. Using optical coherence tomography, retinal nerve fiber layer thickness between groups was found to be comparable; the ganglion cell complex was thicker in the control patients, and there was no significant difference between groups for choroid foveal loss volume. Mean blood flow velocity in the vortex veins had the highest area under receiver operating characteristic curve (1.0) and z-value (5.35). Diastolic blood flow velocity in the central retinal artery had a diagnostic value of 2.74 and area under receiver operating characteristic curve of 0.73. The authors concluded that this study suggested a diagnostic benefit in measuring blood flow velocities.

Witkowska et al (2017) investigated blood flow regulation using laser speckle flowgraphy in 27 individuals.<sup>13</sup> In this prospective study, the authors specifically looked at mean blur rate blood flow in the optic nerve head and a peripapillary region. First, participants' blood flow was measured when they were in a sitting position; then, participants were asked to perform an isometric "squatting" exercise for 6 minutes. Compared with baseline (sitting), exercise significantly increased ocular perfusion blood pressure (78.5%), mean blur rate in the tissue of



the optic nerve head (18.1%), and mean blur rate in the peripapillary region (21.1+8.3%) ( $p<.001$ ). Few studies have used laser speckle flowgraphy to study autoregulation of ocular blood flow during a change in blood pressure, and this study is limited to Japanese populations. Despite the lack of literature and limited population, the authors noted laser speckle flowgraphy could be a valuable tool to study the regulation of blood flow in the optic nerve head, particularly in patients suspected of having glaucoma or patients who have glaucoma.

Rusia et al (2011) reported on use of color doppler imaging in normal and glaucomatous eyes.<sup>14</sup> Using data from other studies, a weighted mean was derived for the peak systolic velocity, end-diastolic velocity, and Pourcelot Resistive Index in the ophthalmic, central retinal, and posterior ciliary arteries. Data from 3061 glaucoma patients and 1 072 controls were included. Mean values for glaucomatous eyes were within 1 standard deviation of the values for controls for most color doppler imaging parameters. Methodologic differences created interstudy variance in color doppler imaging values, complicating the construction of a normative database and limiting its utility. The authors noted that because the mean values for glaucomatous and normal eyes had overlapping ranges, caution should be used when classifying glaucoma status based on a single color doppler imaging measurement.

**Table 5. Summary of Key Nonrandomized Study Characteristics**

Study	Study Type	Country	Dates	Participants	Treatment 1	Treatment 2	Follow-Up
Kuryшева et al (2017) <sup>12</sup> ,	Prospective	Russia	NR	Patients with pre-perimetric glaucoma (n=32) and age-matched controls (n=30). All patients were White.	Optical coherence tomography	N/A	NR
Witkowska et al (2017) <sup>13</sup> ,	Prospective	Austria	2015-2016	Healthy participants (N=27). All participants were White.	Laser speckle flowgraphy	N/A	6 minutes

N/A: not applicable; NR: not reported.

**Table 6. Summary of Key Nonrandomized Study Results**

Study	AUC and Diagnostic Value AUC; p-value	Increase in OPP from Baseline	Increase in MTONH from Baseline	Increase in MTPPR from Baseline
Kuryшева et al (2017) <sup>12</sup> ,		NR	NR	NR
MBFV in VV	1.0; <.0001			

Study	AUC and Diagnostic Value AUC; p-value	Increase in OPP from Baseline	Increase in MTONH from Baseline	Increase in MTPPR from Baseline
MBFV in CRV	0.85;.0001			
DBFV in CRA	0.73;.006			
DBFV in LSPCAs	0.71;.011			
Witkowska et al (2017) <sup>13</sup> ,	NR	78.5+/-19.8%	18.1+/-7.7%	21.1+/-8.3%

AUC: area under the receiver operating characteristic curve; CRA: central retinal artery; CRV: central retinal vein; DBFV: diastolic blood flow velocity; LSPCA: lateral short posterior ciliary artery; MBFV: mean blood flow velocity; MTPPR: mean blur rate in the peripapillary region; MTONH: mean blur rate in the tissue of the optic nerve head; NR: not reported; OPP: ocular perfusion pressure; VV: vortex veins.

**Table 7. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-up <sup>e</sup>
Kuryshva et al (2017) <sup>12</sup> ,	3. Study population included healthy controls; 4. Enrolled populations do not reflect relevant diversity		3. Intervention applied to all patients; No test utilized as comparator	5. Adverse events of test not described	1. Follow-up not reported
Witkowska et al (2017) <sup>13</sup> ,	3. Study population was healthy individuals; 4. Enrolled populations do not reflect relevant diversity		3. No test utilized as comparator	5. Adverse events of test not described	1. Follow-up evaluated short-term changes only

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

<sup>c</sup> Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

<sup>d</sup> Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

<sup>e</sup> Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

**Table 8. Study Design and Conduct Limitations**

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Data Completeness <sup>e</sup>	Statistical <sup>f</sup>
Kuryшева et al (2017) <sup>12</sup> ,	1. Selection of patients not described; 2. Selection of control subjects was not randomized, but based on person accompanying patients	1. Examiner not blinded to patient group	4. Evaluator description not provided			
Witkowska et al (2017) <sup>13</sup> ,	1. Selection of patients not described	1. All patients were healthy and underwent same treatment, therefore no blinding was utilized				2. Comparison to other tests not included in study, since no comparator utilized

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

<sup>b</sup> Blinding key: 1. Not blinded to results of reference or other comparator tests.

<sup>c</sup> Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

<sup>d</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>e</sup> Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

<sup>f</sup> Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, more effective therapy, or avoid unnecessary therapy or testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

The clinical utility of techniques to evaluate ocular blood flow is similar to that for other imaging techniques. The objective is to improve the diagnosis and direct management of patients with glaucoma or suspected glaucoma. Measures of ocular blood flow may have particular utility for the diagnosis and monitoring of normal tension glaucoma.

The only longitudinal study identified is a study by Calvo et al (2012) on the predictive value of retrobulbar blood flow velocities in a prospective series of 262 patients who were glaucoma suspect.<sup>15</sup> At baseline, all participants had normal visual field, increased IOP (mean, 23.56 mm Hg), and glaucomatous optic disc appearance. Blood flow velocities were measured by color doppler imaging during the baseline examination, and conversion to glaucoma was assessed at least yearly according to changes observed with confocal scanning laser ophthalmoscopy. During the 48-month follow-up, 36 (13.7%) patients developed glaucoma and 226 did not. Twenty (55.5%) of those who developed glaucoma also showed visual field worsening (moderate agreement,  $\kappa=0.38$ ). Mean end-diastolic and mean velocity in the ophthalmic artery were significantly reduced at baseline in subjects who developed glaucoma compared with subjects who did not.

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The evidence does not permit any inferences about the utility of ocular blood flow evaluation in the evaluation of glaucoma.

### **Section Summary: Evaluation of Ocular Blood Flow**

Techniques to measure ocular blood flow or ocular blood velocity are being evaluated for the diagnosis of glaucoma. Data for these techniques remain limited. Current literature focuses on which technologies are most reliably associated with glaucoma. Literature reviews have not identified studies that suggest whether these technologies improve the diagnosis of glaucoma or whether measuring ocular blood flow in patients with glaucoma or suspected glaucoma improves health outcomes.

### **Summary of Evidence**

For individuals who have glaucoma or suspected glaucoma who receive imaging of the optic nerve and retinal nerve fiber layer, the evidence includes studies on diagnostic accuracy. Relevant outcomes are test accuracy, symptoms, morbid events, functional outcomes, and medication use. Confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography can be used to evaluate the optic nerve and retinal nerve fiber layer in patients with glaucoma and suspected glaucoma. Numerous articles have described findings from patients with known and suspected glaucoma using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography. These studies have reported that abnormalities may be detected on these examinations before functional changes are noted. The literature and specialty society guidelines have indicated that optic nerve analysis using confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography are established add-on tests that may be used to diagnose and manage patients with glaucoma and suspected glaucoma. These results are often considered along with other findings to make diagnostic and therapeutic decisions about glaucoma care,

including the use of topical medication, monitoring, and surgery to lower intraocular pressure. Thus, an accurate diagnosis of glaucoma would be expected to reduce the progression of glaucoma. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome

For individuals who have glaucoma or suspected glaucoma who receive an evaluation of ocular blood flow, the evidence includes association studies. Relevant outcomes are test accuracy, symptoms, morbid events, functional outcomes, and medication use. Techniques to measure ocular blood flow or ocular blood velocity are used to determine appropriate glaucoma treatment options. The data for these techniques remain limited. Literature reviews have not identified studies addressing whether these technologies improve diagnostic accuracy or whether they improve health outcomes in patients with glaucoma. Some have suggested that these parameters may inform understanding of the variability in visual field changes in patients with glaucoma (i.e., they may help explain why patients with similar levels of intraocular pressure develop markedly different visual impairments). However, data on the use of ocular blood flow, pulsatile ocular blood flow, and/or blood flow velocity are currently lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

#### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In 2009, clinical input was sought to help determine whether the use of optic nerve or retinal nerve fiber layer imaging or ocular blood flow evaluation for individuals with glaucoma or suspected glaucoma would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 4 respondents, including 1 physician specialty society and 3 academic medical centers.

For individuals who have glaucoma or suspected glaucoma who receive imaging of the nerve and retinal nerve fiber layer, clinical input supports that this use provides a clinically meaningful improvement in net health outcome and indicates that this use is consistent with generally accepted medical practice. Most reviewers supported the use of confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography in the care of patients with glaucoma and those with suspected glaucoma. Reviewers provided data to demonstrate that this testing is equivalent to expert assessment of optic disc photography for both detecting glaucoma and showing disease progression. Reviewers also commented on favorable aspects of this testing. For example, unlike other glaucoma testing, these tests can be done more easily (e.g., testing does not always need to be done with dilated pupils) and ambient light level may be (is) less critical. In addition, while serial stereo photographs of the optic nerves are considered by many as the criterion standard, they are not always practical,

especially for general ophthalmologists. This testing also requires less cooperation from the patient, which can help when evaluating some older patients.

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American Academy of Ophthalmology

In 2020, the American Academy of Ophthalmology issued 2 preferred practice patterns on primary open-angle glaucoma suspect and primary open-angle glaucoma, both recommending evaluation of the optic nerve and retinal nerve fiber layer.<sup>16,16</sup> The documents stated that stereoscopic visualization and computer-based imaging of the optic nerve head and retinal nerve fiber layer provide different information about the optic nerve and are complementary. Both imaging methods are useful adjuncts as part of a comprehensive clinical examination. The guidelines described 3 types of computer-based imaging devices (confocal scanning laser ophthalmoscopy, scanning laser polarimetry, optical coherence tomography) currently available for glaucoma, which are similar in their ability to distinguish glaucoma from controls and noted that "computer-based digital imaging of the optic nerve head and retinal nerve fiber layer is routinely used to provide quantitative information to supplement the clinical examination of the optic nerve.... computerized imaging may be useful to distinguish between glaucomatous and nonglaucomatous retinal nerve fiber layer thinning." In addition, the Academy concluded that, as device technology evolves, the performance of diagnostic imaging devices is expected to improve.

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 9.

**Table 9. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<i>Ongoing</i>			
NCT04646122	Predicting Glaucoma Progression with Optical Coherence Tomography Structural and Angiographic Parameters	100	Mar 2022
NCT01957267	Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma	160	Dec 2024
<i>Unpublished</i>			
NCT02178085	Ocular Blood Flow Assessment in Glaucoma (OBAMAg)	62	Sep 2019

NCT: national clinical trial.

**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
92133	Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve
92134	Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina
0198T	Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report

<b>ICD-10 DIAGNOSES</b>	
A18.53	Tuberculous chorioretinitis
B39.4	Histoplasmosis capsulati, unspecified
B39.9	Histoplasmosis, unspecified
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid
D31.31	Benign neoplasm of right choroid
D31.32	Benign neoplasm of left choroid
E08-E13	Diabetes mellitus, code range
H21.551	Recession of chamber angle, right eye
H21.552	Recession of chamber angle, left eye
H21.553	Recession of chamber angle, bilateral
H30-H36	Disorders of choroid and retina, code range
H40.001-H42	Glaucoma, code range
H43-H44	Disorders of vitreous body and globe, code range
H47	Optic nerve and visual pathways, code range
H53.411	Scotoma involving central area, right eye
H53.412	Scotoma involving central area, left eye
H53.413	Scotoma involving central area, bilateral
H59.031	Cystoid macular edema following cataract surgery, right eye
H59.032	Cystoid macular edema following cataract surgery, left eye
H59.033	Cystoid macular edema following cataract surgery, bilateral
Q15.0	Congenital glaucoma
Z79.899	Other long term (current) drug therapy

<b>REVISIONS</b>	
04-19-2007 effective 07-01-2007	<ul style="list-style-type: none"> <li>▪ Added the indications for OCT use for diagnosing and monitoring glaucoma, nerve fiber, and optic nerve conditions.</li> </ul>
05-09-2007 effective 11-01-2007	<ul style="list-style-type: none"> <li>▪ The policy section was updated to split the first bullet under B. to create two bullets, one for age-related macular degeneration and one for diabetic macular edema and to set a maximum number of OCT services per year for each.</li> </ul>
04-30-2010	<p>In Policy Section:</p> <ul style="list-style-type: none"> <li>▪ Revised repeat testing For Diabetic Macular Edema (DME), from "Repeat every 2 or 3 months" to "Repeat every 3 or 4 months"</li> <li>▪ Revised repeat testing For Epiretinal Membrane (ERM) from "pre-treatment and post-surgical at 3 months, 6 months" to "pre-treatment and post-surgical after 6 weeks, 6 months".</li> <li>▪ Added "If Cystoid Macular Edema: Repeat every 2 months during acute treatment."</li> <li>▪ Added "If Branch Retinal Vein Occlusion: Repeat every 3 or 4 months indefinitely."</li> <li>▪ Added "If Central Retinal Vein Occlusion: Repeat every 3 or 4 months for approximately 2 years"</li> <li>▪ Added "If Macular Drusen: Repeat annually, allowing one study by treating MD / DO per year."</li> <li>▪ Corrected wording of "treating MD / OD" to "treating MD / DO"</li> </ul> <p>In Coding Section:</p> <ul style="list-style-type: none"> <li>▪ Updated wording for CPT code 92135.</li> <li>▪ Confirmed no diagnosis codes listed for OCT for the rhegmatogenous retinal detachment (361.00-361.07)</li> <li>▪ Added diagnosis code 362.51.</li> </ul>
10-26-2010	<p>In Policy Section:</p> <ul style="list-style-type: none"> <li>▪ Item A, inserted ", retinal conditions" to read "Scanning Laser Ophthalmoscopy (SLO) test is allowable for the diagnoses and the monitoring of the optic nerve, retinal conditions, and glaucoma."</li> <li>▪ Item B, #1 through #3, removed "by treating MD/DO" to read: <ol style="list-style-type: none"> <li>1. If Exudative Age-related Macular Degeneration (AMD): Repeat OCT will significantly help guide the need for retreatment (with photodynamic therapy [PDT] or intravitreal injections) in conjunction with intravenous fluorescein angiography (IVF) / indocyanine green (ICG). Maximum of 8 per year linked to intravitreal injections.</li> <li>2. If Diabetic Macular Edema (DME): Repeat 3 or 4 months (maximum of 4 per year linked to intravitreal injections / or laser treatment.</li> <li>3. If Retinal Detachment (RD): Repeat pre-treatment and post-surgical at 2 months (maximum of 2).</li> <li>4. If Epiretinal Membrane (ERM): Repeat pre-treatment and post-surgical after 6 weeks, 6 months (maximum of 3) if with macular edema.</li> </ol> </li> <li>▪ Item B, #7, replaced "indefinitely," with "for approximately two years." To read "Repeat every 3 or 4 months for approximately two years."</li> <li>▪ Item B, #9, replaced "allowing one study by treating MD/DO per year" with "if subjective visual changes or suspicion of choroidal neovascularization: if more than two studies per year, then documentation is required" to read "Repeat annually, if subjective visual changes or suspicion of choroidal neovascularization: if more than two studies per year, then documentation is required."</li> </ul> <p>In the Medical Policy Title Section:</p>



<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>Replaced "Scanning Laser Ophthalmoscopy (SLO) for Glaucoma and Optical Coherence Tomography (OCT) for Retinal Conditions" with "Scanning Computerized Ophthalmic Diagnostic Imaging Devices."</li> </ul>
02-16-2011	In Coding section: <ul style="list-style-type: none"> <li>Added CPT codes: 92133, 92134, 92227, 92228.</li> <li>Removed CPT code: 92135.</li> </ul>
01-01-2012	In the Coding section: <ul style="list-style-type: none"> <li>Removed HCPCS code: S0625</li> </ul>
01-15-2013	In the Policy section: In Item B, revised the following statement, " <u>Optical Coherence (OCT) test is allowed for the diagnoses and the monitoring for retinal conditions.</u> " to " <u>Optical Coherence (OCT) test is allowed for the diagnoses, listed below, monitoring for retinal conditions, and ocular toxicity secondary to high-risk medications (i.e., chloroquine [Aralen], hydroxychloroquine [Plaquenil], Interferon alpha-2b, Amiodarone, tamoxifen citrate [Nolvadex], fingolimod [Gilenya], Seroquel).</u> "
	In Coding section: <ul style="list-style-type: none"> <li>Added Diagnosis codes: 362.57, 379.21, V58.69.</li> </ul>
01-22-2013	Corrections were made to the Current Effective Date and the Revision Date section.
07-30-2013	In Policy section: <ul style="list-style-type: none"> <li>Item B, 9 moved to become new #2.</li> <li>In new Item B, 2, inserted "only" to read "Repeat annually, only if subjective visual changes..."</li> </ul>
	In Coding section: <ul style="list-style-type: none"> <li>Added ICD-10 Diagnosis codes (<i>Effective October 1, 2014</i>)</li> </ul>
	Updated Reference section.
04-28-2015	Updated Description section.
	Added Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>Added 377.14 to ICD-9 Diagnosis codes</li> <li>Added H47.231-H47.233 to ICD-10 Diagnosis codes.</li> </ul>
	Updated References section.
08-19-2015	In Policy section: <ul style="list-style-type: none"> <li>In Item B 3, added "8" and removed "Repeat every 3 or 4 months" and "4", to read "Maximum of 8 per year linked to intravitreal injections or laser treatment."</li> <li>In Item B 5, removed "after 6 weeks, 6 months", and "3", to read "Repeat pre-treatment and post-surgical (maximum of 4 per year) if with macular edema."</li> <li>In Item B 6, removed "at 2 or 3 months" and added "maximum of 4 per year) in", to read "Repeat pre-treatment and post-treatment (maximum of 4 per year) in cases of partially closed hole."</li> <li>In Item B 8, removed "Repeat every 3 or 4 months for approximately 2 years" and added "Maximum of 8 per year linked to intravitreal injections"</li> <li>In Item B 9, removed "Repeat every 3 or 4 months for approximately 2 years" and added "Maximum of 8 per year linked to intravitreal injections"</li> </ul>
	Updated Rationale section.
10-01-2015	Policy published 11-25-2015. Effective 10-01-2015 with ICD-10 coding implementation.
	In Coding section: <ul style="list-style-type: none"> <li>Removed ICD-10 diagnosis codes: H40.009, H40.141, H40.142, H40.143, H40.1511, H40.1512, H40.1513, H40.1514, H40.1521, H40.1522, H40.1523, H40.1524, H40.1531, H40.1532, H40.1533, H40.1534</li> </ul>

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>Added ICD-10 diagnosis codes: H35.361, H35.362, H35.363, H40.1411, H40.1412, H40.1413, H40.1414, H40.1421, H40.1422, H40.1423, H40.1424, H40.1431, H40.1432, H40.1433, H40.1434, H40.151, H40.152, H40.153, Z79.899</li> </ul>
10-01-2015	<p>Policy published 05-25-2016. Retro-effective to 10-01-2015 with ICD-10 coding implementation.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added ICD-10 diagnosis codes: H40.021, H40.022, H40.023, H40.31X1, H40.31X2, H40.31X3, H40.31X4, H40.32X1, H40.32X2, H40.32X3, H40.32X4, H40.33X1, H40.33X2, H40.33X3, H40.33X4, H40.41X1, H40.41X2, H40.41X3, H40.41X4, H40.42X1, H40.42X2, H40.42X3, H40.42X4, H40.43X1, H40.43X2, H40.43X3, H40.43X4.</li> </ul>
10-01-2016	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>Added ICD-10 codes effective 10-01-2016: E08.3211, E08.3212, E08.3213, E08.3291, E08.3292, E08.3293, E08.3311, E08.3312, E08.3313, E08.3391, E08.3392, E08.3393, E08.3411, E08.3412, E08.3413, E08.3491, E08.3492, E08.3493, E08.3511, E08.3512, E08.3513, E08.3521, E08.3522, E08.3523, E08.3531, E08.3532, E08.3533, E08.3541, E08.3542, E08.3543, E08.3551, E08.3552, E08.3553, E08.3591, E08.3592, E08.3593, E08.37X1, E08.37X2, E08.37X3, E09.3211, E09.3212, E09.3213, E09.3291, E09.3292, E09.3293, E09.3311, E09.3312, E09.3313, E09.3391, E09.3392, E09.3393, E09.3411, E09.3412, E09.3413, E09.3491, E09.3492, E09.3493, E09.3511, E09.3512, E09.3513, E09.3521, E09.3522, E09.3523, E09.3531, E09.3532, E09.3533, E09.3541, E09.3542, E09.3543, E09.3551, E09.3552, E09.3553, E09.3591, E09.3592, E09.3593, E09.37X1, E09.37X2, E09.37X3, E10.3211, E10.3212, E10.3213, E10.3291, E10.3292, E10.3293, E10.3311, E10.3312, E10.3313, E10.3391, E10.3392, E10.3393, E10.3411, E10.3412, E10.3413, E10.3491, E10.3492, E10.3493, E10.3511, E10.3512, E10.3513, E10.3521, E10.3522, E10.3523, E10.3531, E10.3532, E10.3533, E10.3541, E10.3542, E10.3543, E10.3551, E10.3552, E10.3553, E10.3591, E10.3592, E10.3593, E10.37X1, E10.37X2, E10.37X3, E11.3211, E11.3212, E11.3213, E11.3291, E11.3292, E11.3293, E11.3311, E11.3312, E11.3313, E11.3391, E11.3392, E11.3393, E11.3411, E11.3412, E11.3413, E11.3491, E11.3492, E11.3493, E11.3511, E11.3512, E11.3513, E11.3521, E11.3522, E11.3523, E11.3531, E11.3532, E11.3533, E11.3541, E11.3542, E11.3543, E11.3551, E11.3552, E11.3553, E11.3591, E11.3592, E11.3593, E11.37X1, E11.37X2, E11.37X3, E13.3211, E13.3212, E13.3213, E13.3291, E13.3292, E13.3293, E13.3311, E13.3312, E13.3313, E13.3391, E13.3392, E13.3393, E13.3411, E13.3412, E13.3413, E13.3491, E13.3492, E13.3493, E13.3511, E13.3512, E13.3513, E13.3521, E13.3522, E13.3523, E13.3531, E13.3532, E13.3533, E13.3541, E13.3542, E13.3543, E13.3551, E13.3552, E13.3553, E13.3591, E13.3592, E13.3593, E13.37X1, E13.37X2, E13.37X3, H34.8110, H34.8111, H34.8112, H34.8120, H34.8121, H34.8122, H34.8130, H34.8131, H34.8132, H34.8310, H34.8311, H34.8312, H34.8320, H34.8321, H34.8322, H34.8330, H34.8331, H34.8332, H35.3110, H35.3111, H35.3112, H35.3113, H35.3114, H35.3120, H35.3121, H35.3122, H35.3123, H35.3124, H35.3130, H35.3131, H35.3132, H35.3133, H35.3134, H35.3210, H35.3211, H35.3212, H35.3213, H35.3220, H35.3221, H35.3222, H35.3223, H35.3230, H35.3231, H35.3232, H35.3233, H40.1110, H40.1111, H40.1112, H40.1113, H40.1114, H40.1120, H40.1121, H40.1122, H40.1123, H40.1124, H40.1130, H40.1131, H40.1132, H40.1133, H40.1134</li> </ul>

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ Termed ICD-10 codes effective 09-30-2016: E08.321, E08.331, E08.341, E08.351, E08.359, E09.321, E09.331, E09.341, E09.351, E09.359, E10.321, E10.331, E10.339, E10.341, E10.349, E10.351, E10.359, E11.321, E11.331, E11.339, E11.341, E11.349, E11.351, E11.359, E13.321, E13.331, E13.339, E13.341, E13.349, E13.351, E13.359, H34.811, H34.812, H34.813, H34.831, H34.832, H34.833, H35.051, H35.32, H40.11X1, H40.11X2, H40.11X3, H40.11X4</li> </ul>
	Updated References section.
10-12-2016	Updated Description section.
	Updated Rationale section.
	Updated References section.
05-12-2017	Updated Description section.
	In Policy section: <ul style="list-style-type: none"> <li>▪ In Item B, removed "diagnosis" and "and the" and added "diagnoses, listed below" and ", and ocular toxicity secondary to high-risk medications (i.e., chloroquine [Aralen], hydroxychloroquine [Plaquenil], Interferon alpha-2b, Amiodarone, tamoxifen citrate [Nolvadex], fingolimod [Gilenya], Seroquel)" to read, "Optical Coherence Tomography (OCT) test is allowed for the diagnoses, listed below, and the monitoring for retinal conditions, and ocular toxicity secondary to high-risk medications (i.e., chloroquine [Aralen], hydroxychloroquine [Plaquenil], Interferon alpha-2b, Amiodarone, tamoxifen citrate [Nolvadex], fingolimod [Gilenya], Seroquel)." <i>(These revisions to policy language were inadvertently removed in the revision of 07-30-2013.)</i></li> </ul>
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added CPT code: 0198T.</li> <li>▪ Removed CPT codes: 92227, 92228.</li> <li>▪ Added ICD-10 codes: H33.001, H33.002, H33.003, H33.011, H33.012, H33.013, H33.021, H33.022, H33.023, H33.031, H33.032, H33.033, H33.041, H33.042, H33.043, H33.051, H33.052, H33.053, H35.50, H35.51, H35.53, H35.54, H43.811, H43.812, H43.813, H47.031, H47.032, H47.033, H47.20, H47.211, H47.212, H47.213, H47.22, H47.291, H47.292, H47.293, H47.321, H47.322, H47.323, H47.331, H47.332, H47.333, H47.391, H47.392, H47.393.</li> </ul>
	In Revision section, revision date was changed from "01-15-2012" to "01-15-2013."
	Updated References section.
10-01-2017	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: H44.2A1, H44.2A2, H44.2A3, H44.2B1, H44.2B2, H44.2B3, H44.2C1, H44.2C2, H44.2C3, H44.2D1, H44.2D2, H44.2D3, H44.2E1, H44.2E2, H44.2E3.</li> </ul>
04-11-2018	Updated Description section.
	Updated Rationale section.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Removed ICD-9 codes.</li> </ul>
	Updated References section.
08-01-2018	In Policy section: <ul style="list-style-type: none"> <li>▪ Added new Item B 10, "If Vitreomacular Traction / Adhesion: Maximum of 4 per year."</li> </ul>
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: H43.821, H43.822, H43.823.</li> </ul>
	Updated References section.
04-15-2019	Policy published to the bcbsks.com website on 03-27-2019 with an effective date of 04-15-2019.

<b>REVISIONS</b>	
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 code: H35.051.</li> </ul>
09-27-2019	Policy published to the bcbsks.com website on 08-28-2019 with an effective date of 09-29-2019.
	In Coding section: <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: H59.031, H59.032, H59.033.</li> </ul>
05-05-2021	Updated Description section.
	Updated Rationale section.
	Updated References section.
07-12-2022	Updated Description Section
	Update Rationale Section
	Updated Coding Section <ul style="list-style-type: none"> <li>• Converted ICD-10 codes to ranges</li> </ul>
	Updated References Section

## REFERENCES

1. Mohindroo C, Ichhpujani P, Kumar S. Current Imaging Modalities for assessing Ocular Blood Flow in Glaucoma. J Curr Glaucoma Pract. Sep-Dec 2016; 10(3): 104-112. PMID 27857490
2. Ervin AM, Boland MV, Myrowitz EH, et al. Screening for Glaucoma: Comparative Effectiveness (Comparative Effectiveness Review No. 59). Rockville, MD: Agency for Healthcare Research and Quality; 2012.
3. Michelessi M, Lucenteforte E, Oddone F, et al. Optic nerve head and fibre layer imaging for diagnosing glaucoma. Cochrane Database Syst Rev. Nov 30 2015; (11): CD008803. PMID 26618332
4. Lin SC, Singh K, Jampel HD, et al. Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology. Ophthalmology. Oct 2007; 114(10): 1937-49. PMID 17908595
5. Shiga Y, Omodaka K, Kunikata H, et al. Waveform analysis of ocular blood flow and the early detection of normal tension glaucoma. Invest Ophthalmol Vis Sci. Nov 21 2013; 54(12): 7699-706. PMID 24130177
6. Bafa M, Lambrinakis I, Dayan M, et al. Clinical comparison of the measurement of the IOP with the ocular blood flow tonometer, the Tonopen XL and the Goldmann applanation tonometer. Acta Ophthalmol Scand. Feb 2001; 79(1): 15-8. PMID 11167279
7. Schmidl D, Garhofer G, Schmetterer L. The complex interaction between ocular perfusion pressure and ocular blood flow - relevance for glaucoma. Exp Eye Res. Aug 2011; 93(2): 141-55. PMID 20868686
8. Harris A, Kagemann L, Ehrlich R, et al. Measuring and interpreting ocular blood flow and metabolism in glaucoma. Can J Ophthalmol. Jun 2008; 43(3): 328-36. PMID 18443609
9. WuDunn D, Takusagawa HL, Sit AJ, et al. OCT Angiography for the Diagnosis of Glaucoma: A Report by the American Academy of Ophthalmology. Ophthalmology. Aug 2021; 128(8): 1222-1235. PMID 33632585
10. Gu C, Li A, Yu L. Diagnostic performance of laser speckle flowgraphy in glaucoma: a systematic review and meta-analysis. Int Ophthalmol. Nov 2021; 41(11): 3877-3888. PMID 34327617
11. Abegao Pinto L, Willekens K, Van Keer K, et al. Ocular blood flow in glaucoma - the Leuven Eye Study. Acta Ophthalmol. Sep 2016; 94(6): 592-8. PMID 26895610

12. Kuryшева NI, Parshunina OA, Shatalova EO, et al. Value of Structural and Hemodynamic Parameters for the Early Detection of Primary Open-Angle Glaucoma. *Curr Eye Res.* Mar 2017; 42(3): 411-417. PMID 27341295
13. Witkowska KJ, Bata AM, Calzetti G, et al. Optic nerve head and retinal blood flow regulation during isometric exercise as assessed with laser speckle flowgraphy. *PLoS One.* 2017; 12(9): e0184772. PMID 28898284
14. Rusia D, Harris A, Pernic A, et al. Feasibility of creating a normative database of colour Doppler imaging parameters in glaucomatous eyes and controls. *Br J Ophthalmol.* Sep 2011; 95(9): 1193-8. PMID 21106991
15. Calvo P, Ferreras A, Polo V, et al. Predictive value of retrobulbar blood flow velocities in glaucoma suspects. *Invest Ophthalmol Vis Sci.* Jun 22 2012; 53(7): 3875-84. PMID 22589447
16. American Academy of Ophthalmology. Preferred Practice Pattern: Primary open-angle glaucoma. 2020; <https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp>. Accessed January 26, 2022.

#### **OTHER REFERENCES**

1. Medical Advisory Committee-Consent Ballot from Ophthalmology and Optometry Liaison Committees, April 19, 2007.
2. Blue Cross and Blue Shield of Kansas Ophthalmology Liaison Committee minutes, May 9, 2007.
3. Medical Advisory Committee (MAC) minutes, August 2, 2007.
4. Blue Cross and Blue Shield of Kansas Ophthalmology Liaison Committee CB, May 2009; July 2009; August 2010.
5. Blue Cross and Blue Shield of Kansas Ophthalmology Liaison Committee, May 2010; May 2013; May 2014; May 2015; June 2016.
6. Blue Cross and Blue Shield of Kansas Optometry Liaison Committee, June 2010; May 2013; August 2016.
7. Blue Cross and Blue Shield of Kansas Ophthalmology/Optometry Liaison Committee, February 2017; May 2018; August 2019.